​

Dyne Therapeutics Ownership | Who Owns Dyne Therapeutics?


OverviewForecastFinancialsChart

Dyne Therapeutics Ownership Summary


Dyne Therapeutics is owned by 116.14% institutional investors, 0.25% insiders. T. rowe price investment management is the largest institutional shareholder, holding 18.73% of DYN shares. T. Rowe Price US Small-Cap Core Equity is the top mutual fund, with 4.24% of its assets in Dyne Therapeutics shares.

DYN Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockDyne Therapeutics116.14%0.25%-16.39%
SectorHealthcare Stocks 247.07%12.15%-159.22%
IndustryBiotech Stocks 385.89%11.79%-297.68%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
T. rowe price investment management30.91M18.73%$686.56M
Janus henderson group13.65M10.63%$247.43M
Blackrock7.39M9.11%$260.69M
Blackrock funding, inc. /de14.47M8.75%$233.14M
Vanguard group11.22M7.91%$219.38M
Fmr11.15M6.74%$179.57M
State street8.16M4.93%$131.43M
Vanguard capital management7.55M4.56%$121.67M
Orbis allan gray7.01M4.25%$155.62M
Vanguard portfolio management4.69M2.84%$75.58M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Mpm asset management682.38K19.40%$8.63M
Fcpm iii services b.v.3.85M11.39%$85.47M
Atlas venture life science advisors3.44M8.78%$55.43M
Palo alto investors lp1.65M5.06%$36.59M
University of wisconsin foundation313.56K3.46%$5.05M
Saturn v capital management1.06M3.37%$23.49M
Bioimpact capital1.92M2.60%$42.69M
Tcg crossover management4.62M2.46%$102.50M
Logos global management lp2.55M2.44%$56.64M
Lion point capital, lp18.00K1.91%$399.78K

Top Buyers

HolderShares% AssetsChange
Blackrock funding, inc. /de14.47M0.00%2.07M
Blackrock7.39M0.01%2.00M
Paradigm biocapital advisors lp1.90M0.68%1.90M
Price t rowe associates inc /md/3.94M0.01%1.61M
Vanguard group11.22M0.00%1.46M

Top Sellers

HolderShares% AssetsChange
Ra capital management---9.71M
Atlas venture life science advisors3.44M8.78%-3.36M
Holocene advisors, lp---2.35M
Perceptive advisors2.69M0.90%-1.98M
Jefferies financial group---1.80M

New Positions

HolderShares% AssetsChangeValue
Paradigm biocapital advisors lp1.90M0.68%1.90M$24.02M
Novo960.39K1.24%960.39K$21.33M
Nantahala capital management382.44K0.19%382.44K$6.16M
Granahan investment management338.56K0.27%338.56K$7.52M
Jones hill capital lp300.90K0.82%300.90K$4.85M

Sold Out

HolderChange
Dunhill financial-1.00
Hfm investment advisors-3.00
Nelson, van denburg & campbell wealth management group-9.00
Creative financial designs inc /adv-10.00
J.safra asset management-11.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20262537.20%191,678,1382.03%1160.90%140-2.78%7421.31%
Mar 31, 2026229-4.58%186,215,3694.65%1440.92%139-9.74%607.14%
Dec 31, 202548-77.78%17,667,612-88.66%120.07%33-77.40%8-80.49%
Sep 30, 202556-72.00%16,926,024-86.84%140.12%39-66.95%9-82.69%
Jun 30, 2025198-5.71%128,546,9735.45%1120.92%116-10.08%5215.56%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
T. Rowe Price US Small-Cap Core Equity7.00M4.24%-7.60K
T. Rowe Price Small-Cap Stock7.90M4.23%491.94K
Vanguard Health Care Inv6.11M3.27%6.11M
Vanguard MStar Total Stk Mkt Idx Invest5.27M2.83%18.00K
Vanguard Total Stock Mkt Idx Inv4.47M2.71%-242.06K
T. Rowe Price Small-Cap Value4.76M2.55%148.60K
State Street® SPDR® S&P® Biotech ETF4.67M2.49%122.13K
Vanguard Morn Total Stk Mkt Idx Investor4.47M2.40%-242.06K
Vanguard US Total Market Shares ETF2.65M2.35%2.40K
T. Rowe Price Instl Small-Cap Stock4.25M2.28%205.98K

Recent Insider Transactions


DateNameRoleActivityValue
Nov 13, 2026Friedl-Naderer Johanna Chief Commercial OfficerSell$3.89K
Nov 13, 2026Kerr Douglas Head of R&D and CMOSell$43.80K
Nov 13, 2026Lucera Erick Chief Financial OfficerSell$33.49K
Oct 02, 2026Posner Brian S-Buy$40.00K
Sep 08, 2026Friedl-Naderer Johanna Chief Commercial OfficerSell$3.49K

Insider Transactions Trends


DateBuySell
2026 Q41-
2026 Q3-27
2026 Q2484
2026 Q138
2025 Q4-3

DYN Ownership FAQ


Who Owns Dyne Therapeutics?

Dyne Therapeutics shareholders are primarily institutional investors at 116.14%, followed by 0.25% insiders and -16.39% retail investors. The average institutional ownership in Dyne Therapeutics's industry, Biotech Stocks , is 385.89%, which Dyne Therapeutics falls below.

Who owns the most shares of Dyne Therapeutics?

Dyne Therapeutics’s largest shareholders are T. rowe price investment management (30.91M shares, 18.73%), Janus henderson group (13.65M shares, 10.63%), and Blackrock (7.39M shares, 9.11%). Together, they hold 38.47% of Dyne Therapeutics’s total shares outstanding.

Does Blackrock own Dyne Therapeutics?

Yes, BlackRock owns 9.11% of Dyne Therapeutics, totaling 7.39M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 260.69M$. In the last quarter, BlackRock increased its holdings by 2M shares, a 37.05% change.

Who is Dyne Therapeutics’s biggest shareholder by percentage of total assets invested?

Mpm asset management is Dyne Therapeutics’s biggest shareholder by percentage of total assets invested, with 19.40% of its assets in 682.38K Dyne Therapeutics shares, valued at 8.63M$.

Who is the top mutual fund holder of Dyne Therapeutics shares?

T. Rowe Price US Small-Cap Core Equity is the top mutual fund holder of Dyne Therapeutics shares, with 4.24% of its total shares outstanding invested in 7M Dyne Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools